These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24247174)

  • 41. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Rosen RC; Giuliano F; Carson CC
    Eur Urol; 2005 Jun; 47(6):824-37. PubMed ID: 15925080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analyzing and Characterizing Why Men Seek Care for Lower Urinary Tract Symptoms.
    Landau A; Welliver C
    Curr Urol Rep; 2020 Oct; 21(12):58. PubMed ID: 33128142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Urological disorders in men: urinary incontinence and benign prostatic hyperplasia.
    Miller SW; Miller MS
    J Pharm Pract; 2011 Aug; 24(4):374-85. PubMed ID: 21984774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic Syndrome and Lower Urinary Tract Symptoms: Epidemiological Study.
    Yoon H
    Low Urin Tract Symptoms; 2012 Mar; 4 Suppl 1():2-7. PubMed ID: 26676692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.
    Parsons JK; Sarma AV; McVary K; Wei JT
    J Urol; 2013 Jan; 189(1 Suppl):S102-6. PubMed ID: 23234610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.
    Fukuta F; Masumori N; Mori M; Tsukamoto T
    BJU Int; 2012 Oct; 110(7):1023-9. PubMed ID: 22233355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Rosen RC; Fitzpatrick JM;
    BJU Int; 2009 Oct; 104(7):974-83. PubMed ID: 19426189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Latest trends and recommendations on epidemiology, diagnosis, and treatment of benign prostatic hyperplasia (BPH)].
    Gabuev A; Oelke M
    Aktuelle Urol; 2011 May; 42(3):167-78. PubMed ID: 21604233
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current pharmacological treatment options for male lower urinary tract symptoms.
    Strittmatter F; Gratzke C; Stief CG; Hedlund P
    Expert Opin Pharmacother; 2013 Jun; 14(8):1043-54. PubMed ID: 23641819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.
    Capitanio U; Salonia A; Briganti A; Montorsi F
    Int J Clin Pract; 2013 Jun; 67(6):544-51. PubMed ID: 23409749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhaled anticholinergic agents and acute urinary retention in men with lower urinary tract symptoms or benign prostatic hyperplasia.
    Vande Griend JP; Linnebur SA
    Ann Pharmacother; 2012 Sep; 46(9):1245-9. PubMed ID: 22851743
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Noninvasive treatment of benign prostatic hyperplasia. Where do we stand in 2005.
    Al-Ansari AA; Shokeir AA
    Saudi Med J; 2006 Mar; 27(3):299-304. PubMed ID: 16532087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Primary and secondary prevention of benign prostatic hyperplasia: current knowledge and implications for clinical management].
    Oelke M; Madersbacher S
    Urologe A; 2011 Oct; 50(10):1257-8, 1260-4. PubMed ID: 21901570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia.
    Parsons JK; Im R
    J Urol; 2009 Oct; 182(4):1463-8. PubMed ID: 19683313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [How to prevent LUTS due to BPH development and progression].
    de la Taille A; Descazeaud A; Robert G
    Prog Urol; 2018 Nov; 28(15):821-829. PubMed ID: 30262262
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.
    Wang C
    Curr Opin Urol; 2010 Jan; 20(1):49-54. PubMed ID: 19887943
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].
    Yuan RQ
    Zhonghua Nan Ke Xue; 2012 Dec; 18(12):1147-51. PubMed ID: 23405801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.